R Squared’s Corbus Pharmaceuticals CRBP Stock Holding History

R Squared’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-760	Closed	-$8.97K	–	563
2024 Q4	$8.97K	Buy	+760	New	+$12.7K	0.01%	1180

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

R Squared's CRBP Position: Q1 2025 in Review

R Squared sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 760 shares — an estimated $8.97K sold.

R Squared first reported a position in CRBP in Q4 2024 and held it in 1 quarter. The position peaked at $8.97K in Q4 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

R Squared reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 760 Corbus Pharmaceuticals shares in Q1 2025, an estimated $8.97K.
R Squared first reported a position in Corbus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Corbus Pharmaceuticals position peaked at $8.97K in Q4 2024.
86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.